Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Mount Sinai Hospital ( Site 0002), New York

Columbia University ( Site 0003), New York

UPMC Hillman Cancer Center ( Site 0013), Pittsburgh

Institut Claudius Regaud ( Site 0051), Toulouse

University of Alabama ( Site 0009), Birmingham

Henry Ford Health System ( Site 0014), Detroit

Institut Curie ( Site 0050), Paris

Mary Crowley Cancer Research Center ( Site 0001), Dallas

Huntsman Cancer Institute ( Site 0004), Salt Lake City

UCLA Medical Center ( Site 0005), Santa Monica

University of California San Francisco ( Site 0007), San Francisco

UCSF ( Site 0015), San Francisco

Institut Gustave Roussy ( Site 0049), Villejuif

Rambam Medical Center ( Site 0041), Haifa

Sheba Medical Center ( Site 0040), Ramat Gan

Severance Hospital ( Site 0103), Seoul

Asan Medical Center ( Site 0104), Seoul

The Royal Marsden Foundation Trust ( Site 0031), London

The Royal Marsden NHS Foundation Trust. ( Site 0032), Sutton